NASDAQ:ENSC
Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc.'s revenue fell 2.8% in fiscal 2025 to $5.1M while operating margin fell to −202.1%. Free cash flow was −$7.9M, −156.5% of revenue, and the diluted share count rose 266.6%.Summary generated from Ensysce Biosciences, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$5.1M
Revenue growth−2.8%
Revenue, 5-yr CAGR+5.2%
Gross marginn/a
Operating margin−202.1%
Net margin−200.8%
ROICn/a
Return on equity−294.0%
Debt / equityn/a
Free cash flow−$7.9M
FCF margin−156.5%
Share count change+266.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 4 | 3 | 2 | 5 | 5 |
| Operating income | −20 | −24 | −11 | −7 | −10 |
| Net income | −29 | −24 | −11 | −8 | −10 |
| Free cash flow | n/a | n/a | n/a | n/a | −8 |
Recent filings
- 8-KAmendment to articles or bylaws
Sep 29, 2026 - 8-KOther events
Aug 25, 2026 - 8-KOther events
Aug 24, 2026 - 4Insider transaction report
Aug 18, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 8-K/AAmended current report
Aug 6, 2026 - 8-KEntry into a material agreement
Aug 6, 2026